Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern우려되는 신종 SARS-CoV-2 변이체에 대한 BIV1-CovIran 비활성화 백신 유도 중화 항체 평가Article Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha antibody assessment B.1.1.7 B.1.351 B.1.617.2 Beta binding domain BIV1-CovIran vaccine candidate vaccine conventional virus neutralization test correlated correlation COVID-19 COVID-19 vaccine Delta delta variant Delta variants demonstrated effective exhibited inactivated individual investigated NAb NAbs neutralization neutralization test neutralize Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody Protein recipient recipients reduction in SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants sensitivity sera serum Spearman the SARS-CoV-2 titre Vaccine vaccinee vaccinees variant variants variants of concern virus neutralization test virus-neutralizing was measured Wuhan strain [DOI] 10.1016/j.cmi.2022.02.030 PMC 바로가기 [Article Type] Article
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination감염 및 예방 접종 후 이종 SARS-CoV-2-중화 활동Article Published on 2022-05-302022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus addition analyzed antibody Antibody Response Antibody responses best Beta Cohort coronavirus COVID-19 COVID-19 vaccination D614G declined decrease Delta dose exceeded greater heterogeneity Hospitalized hospitalized patient hospitalized patients Humoral immunity Immunity Improvements individual infected individual infected individuals infecting Infection lowest mRNA vaccine Mutation N-terminal domain neutralization neutralization titer neutralizing activities Neutralizing activity Neutralizing antibodies neutralizing antibody responses no difference not differ pandemic Patient patients Protein recognize respiratory SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2-neutralizing antibodies SARS-CoV-2-specific antibody responses SARS-CoV-2-specific neutralizing antibodies second vaccination sequence serum sample serum samples severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly significantly lower Specific specific neutralizing antibodies Spike protein symptom onset the SARS-CoV-2 the spike protein vaccinated individual vaccinated individuals Vaccine vaccinee vaccinees variants variants of concern viral strain viral strains virus infection VoC VOCs [DOI] 10.3389/fimmu.2022.888794 PMC 바로가기 [Article Type] Article
Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data이종 불활성화 및 아데노바이러스 매개 COVID-19 백신의 면역원성: 실제 데이터Article Published on 2022-05-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] adenoviral-vectored vaccine adenoviral-vectored vaccines Anti-RBD IgG AZD1222 B.1.1.7 B.1.351 B.1.617.2 CMIA CoronaVac country COVID-19 COVID-19 vaccine elicited ELISA enrolled enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay followed by group Heterologous heterologous vaccine homologous IgG immunoassay immunogenicity inactivated Limited Microparticle neutralization test Neutralizing activity neutralizing antibody participant recipient recipients regimen response SARS-CoV-2 SARS-CoV-2 variants sera serum sample serum samples subset surrogate virus neutralization test sVNT tested the SARS-CoV-2 Vaccine variant variants variants of concern virus neutralization test was tested Wuhan Wuhan strain [DOI] 10.1016/j.vaccine.2022.04.043 PMC 바로가기 [Article Type] Article
Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against OmicronSARS-CoV-2 회복 아동의 장기 면역 및 오미크론에 대한 중화 능력Article Published on 2022-05-172022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] activity Against antibody Antibody Response Antigen Asymptomatic Capacity CD4 T cell CD8 T cell CD8 T cells cellular immune responses children Cohort COVID-19 cross-neutralization D614G declined effectively controlled fold humoral Humoral and cellular immune responses immune immune memory immune responses Immunity IMPROVE induce Infection lack memory T cell memory T cells Mild neutralization neutralize Neutralizing activity Neutralizing antibodies neutralizing antibody omicron pre-existing immunity pre-immune recall remained response robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific T cells seronegative T cell T cells vaccination Vaccine vaccine response variant variants variants of concern [DOI] 10.3389/fimmu.2022.882456 PMC 바로가기 [Article Type] Article
Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities다양한 질병 중증도를 가진 COVID-19 회복기 및 확인된 환자의 SARS-CoV-2 변이체에 대한 체액, 세포 및 사이토카인 면역 반응Article Published on 2022-05-172022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] ADE Against Alpha alpha and delta variants Alpha variant Anti-RBD IgG cellular Cellular immune response cellular immunity chemokine chemokines Confirmed convalescent convalescent sera correlation COVID-19 Cytokines delta variant Delta variants disease disease severity ELISA ELISPOT evaluate exhibited fold greater humoral Humoral and cellular immune responses humoral immune response Humoral immunity IgG IL-6 immune immune response immune responses Immunity immunoassays individual Inflammatory mediators IP-10 MCP-1 mediators multiplex neutralization potency Neutralizing activity Omicron variant Omicron variants Patient patients performed pseudovirus pseudovirus infection quantified Raji cells RBD-specific IgG response risk SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 pseudovirus infection SARS-CoV-2 variant SARS-CoV-2 variants serum severe disease Significant significantly specific antibodies spike-specific antibodies Spike-specific antibody T cell T cells variant virus was measured [DOI] 10.3389/fcimb.2022.862656 PMC 바로가기 [Article Type] Article
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab새로운 인간 중화 mAb는 SARS-CoV-2의 델타, 감마 및 오미크론 변이체를 인식하고 소트로비맙과 함께 사용할 수 있습니다Article Published on 2022-05-162022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE-2 ACE-2 receptor angiotensin angiotensin converting enzyme anti-spike MAbs antibody Can Casirivimab caused Cell culture cell cultures cell entry Clinical use combinatorial treatment combinatorial treatments coronavirus Delta diagnostic drug ENhance epidemics/pandemics epitope Epitopes Gamma glycoprotein Human Imdevimab immune system Infection inhibitory effect Interaction interfere investigated mAb mAbs monoclonal monoclonal antibodies Neutralizing Neutralizing activity neutralizing mAbs. novel omicron Omicron variant pandemic Pandemics Patient RBD Receptor binding domain recognize recognizing SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 virus Scientific community Sotrovimab spike spike glycoprotein Spike-RBD/ACE-2 subsequent the antibody the Spike therapeutic therapy variants virus virus infection [DOI] 10.3390/ijms23105556 PMC 바로가기 [Article Type] Article
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 Research Published on 2022-05-162022-10-05 Journal: Nature [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] addition Antiviral Antiviral compound antiviral drug B.1.1.529 characterization chimeric COVID-19 delta variant dominant effective Effectiveness evaluated expressing hamster hamsters individual isolate less Lineage mice molnupiravir monoclonal antibody Mutation Neutralizing activity omicron organ pathogenicity plasma raised recipient reduction in REGN10933 REGN10987 Replication replicative restrict rodent S309 SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 strains Strains susceptibility the spike protein therapeutic Vaccine Vaccines variant variants viral infection [DOI] 10.1038/s41586-022-04856-1 [Article Type] Research
Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects백신 접종 대상체의 체액성 면역 프로파일링을 위한 SARS-CoV-2 변이 단백질 마이크로어레이 개발Article Published on 2022-05-152022-09-11 Journal: Biosensors & bioelectronics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 anti-spike antibody antibody Antibody responses AZD1222 B.1.1.7 B.1.351 B.1.617 B.1.617.1 B.1.617.2 binding ChAdOx1 chimeric collected correlated D614G demonstrated develop development domain Drug development Extracellular globe host receptor Humoral immunity Humoral response humoral responses IgA IgG IgM isotype IgM isotypes immune inhibiting Microarray MONITOR mRNA-1273 mutant neutralization neutralizing activities Neutralizing activity neutralizing antibody P.1 platform Protein protein microarray Research SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants serology serum spike variants subject the antibody response vaccinated individual vaccination Vaccine Vaccines variant variants variants of concern Virus neutralization wild-type [DOI] 10.1016/j.bios.2022.114067 PMC 바로가기 [Article Type] Article
Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy다양한 COVID-19 백신에 대한 체액 면역 반응 다양성: "그린 패스" 정책에 대한 시사점Article Published on 2022-05-112022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] ACE2 binding activities Ad26 Ad26.COV2.S age Analysis anti-RBD anti-RBD antibody titer antibody Antibody Response Antibody titer appear assumption average binding BNT162b2 booster vaccination ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine ChAdOx1 nCoV-19 vaccines concentrations country COV2.S COVID-19 COVID-19 infection COVID-19 pandemic detect Diversity elicit elicited eligibility epitope evaluated Features green Green Pass Policy heterogeneous humoral humoral immune response immune Immunity implication individual maintain mRNA mRNA-1273 Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody observé Pass peptides Policy Protein Randomly Rapid test rationale RBD RBD-ACE2 reactivity reactogenicity Receptor-binding domain reduce reopening response Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike selected sera serum serum sample significantly spike Spike protein synthetic peptide the receptor-binding domain titer vaccinated individual vaccination Vaccine virus spread [DOI] 10.3389/fimmu.2022.833085 PMC 바로가기 [Article Type] Article
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infectionSARS-CoV-2 감염 18개월 후 1회 투여 mRNA 백신 접종으로 유발된 광범위한 체액 및 세포 면역Article Published on 2022-05-042022-09-11 Journal: BMC Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] analyzed cell-mediated immune response Cell-mediated immune responses Cellular immune response cellular immunity comparable convalescent individual convalescent individuals coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 diagnosis Diagnosis dose elicit elicited Guidance humoral Humoral and cellular immune responses immune response immune responses include Infection mRNA mRNA vaccination mRNA vaccine Neutralizing activity omicron Omicron variant pandemic Patient recruited respiratory SARS-CoV-2 SARS-COV-2 infection second dose second dose of vaccine Severe acute respiratory syndrome severe acute respiratory syndrome-coronavirus-2 significantly vaccination Vaccine vaccine dose vaccine doses variant variants variants of concern were assessed wild-type [DOI] 10.1186/s12916-022-02383-4 PMC 바로가기 [Article Type] Article